Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors

CompletedOBSERVATIONAL
Enrollment

93

Participants

Timeline

Start Date

April 4, 2017

Primary Completion Date

November 2, 2017

Study Completion Date

November 2, 2017

Conditions
Neuroendocrine Tumors
Interventions
OTHER

Data collection

This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.

Trial Locations (8)

11733

National Transitional Research, East Setauket

15212

Allegheny Cancer Center, Pittsburgh

21202

Mercy Medical Center, Baltimore

33612

Moffitt Cancer Center, Tampa

55905

Mayo Clinic, Rochester

67214

Cancer Center of Kansas, Wichita

70121

Ochsner Clinic Foundation, New Orleans

02111

Tufts Medical Center, Boston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Ipsen

INDUSTRY

NCT03112694 - Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter